Gene editing boosts CAR-NK efficacy against leukaemia

German scientists have presented a dual modification strategy that combines CRISPR-Cas9 and CAR technology to enhance the efficacy of natural killer (NK) cells against acute myeloid leukaemia (AML).

By: Gorm Palmgren - Oct. 1, 2024
News

The researchers targeted the CD33 antigen on AML cells using chimeric antigen receptor (CAR)-modified NK cells while simultaneously disrupting the KLRC1 gene by CRISPR-Cas9-mediated knockout. This gene encodes NKG2A, an inhibitory receptor that binds to HLA-E on leukaemic cells, suppressing NK cell activity. By disrupting KLRC1, the team aimed to overcome the immune suppression in the tumour microenvironment and enhance the cytotoxic function of the CAR-NK cells.

Knockout of NKG2A resulted in significantly increased cytotoxicity in CD33-targeted CAR-NK cells, both in vitro and in vivo when tested against AML cell lines and patient-derived primary blasts. Single-cell transcriptomics and epitope analyses confirmed that the engineered cells retained their activation and maturation features, leading to improved anti-leukaemic activity. Additionally, the modified NK cells demonstrated potent killing capacity, enhanced by the elimination of inhibitory signals, which typically dampen NK cell responses.

This research - led by Tobias Bexte and Evelyn Ullrich from the Goethe University Frankfurt - was published yesterday in Nature Communications.

To get more CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagCMN BriefsHashtagNewsHashtagAcute Myeloid Leukemia, AMLHashtagCAR-T

News: Gene editing boosts CAR-NK efficacy against leukaemia
CLINICAL TRIALS
Beta-Thalassemia, BT, (NCT06328764)
Sponsors:
CorrectSequence Therapeutics Co., Ltd
Indicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT06565026)
Sponsors:
CorrectSequence Therapeutics Co., Ltd
Indicator
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine